Topics

Multiple myeloma CAR-T therapy by CARsgen gains RMAT status

05:56 EDT 29 Oct 2019 | SmartBrief

The FDA has conferred the Regenerative Medicine Advanced Therapy designation upon CARsgen Therapeutics' chimeric antigen rece -More

Original Article: Multiple myeloma CAR-T therapy by CARsgen gains RMAT status

NEXT ARTICLE

More From BioPortfolio on "Multiple myeloma CAR-T therapy by CARsgen gains RMAT status"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...